Managing hyperkalemia in at risk, comorbid patients is a frequent challenge for clinicians. In line with the trend of increasing rates of renal disease, heart failure, and diabetes, hyperkalemia is occurring more frequently. Patients on goal-directed medical therapy with RAASi that experience hyperkalemia often have their medications stopped or reduced below target – negatively impacting the therapeutic benefits. Treatment regimens with standard agents have adverse effect profiles that make them ineffective. Modern regimens, with potassium-lowering medications offer patients and clinicians safety and added flexibility; particularly when optimizing RAAsi therapy. The overall goal of the program is to support clinician recognition of the benefits of early initiation of potassium-lowering medications, as part of a multi-step approach to prevent hyperkalemia.
This material has been developed with educational support from CSL Vifor.